Immunomodulators in Dermatology

Which drug is a prodrug and inhibits T-cell proliferation?

Which targeted synthetic DMARD is administered orally and indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and ulcerative colitis?

Which drug is a folate antagonist and is considered first-line for rheumatoid arthritis?

Which drug should be reserved for severe, progressive rheumatoid arthritis that has not responded to safer DMARDs?

Which drug carries a black box warning for fatal toxicities of the bone marrow, liver, lungs, and kidneys?

Which drug is indicated for IV therapy of adults with moderate to severe RA who have not responded to one or more TNF inhibitors?

Which targeted synthetic DMARD carries a black box warning for serious or fatal infection risk, heart-related events, cancer, and blood clots?

Which conventional DMARD has side effects including nausea, hair loss, mouth ulcers, and hepatoxicity?

Which drug is considered a last choice and is used for rejection of transplanted organs?

Which drug is associated with the need for G6PD testing, baseline eye exam, and routine eye screens due to potential toxic retinopathy?

Which type of drugs are biologic DMARDs?

What is the risk associated with all biologic DMARDs?

How are biologic DMARDs manufactured?

What is a type of biologic DMARD?

What is the MOA of adalimumab (Humira)?

What is the MOA of rituximab (Rituxan)?

What is the MOA of abatacept (Orencia)?

For which condition is adalimumab (Humira) indicated?

What is the target of rituximab (Rituxan)?

What is the common risk associated with all biologic DMARDs?

Biologic DMARDs are not immunosuppressive drugs.

Biologic DMARDs are usually combined with methotrexate.

MAbs are proteins derived only from human sources.

Adalimumab is indicated for mild rheumatoid arthritis.

Rituximab binds to and neutralizes tumor necrosis factor (TNF).

Rituximab is indicated for moderate to severe rheumatoid arthritis.

Abatacept is a T-cell activation inhibitor.

Interleukin antagonists are used in the treatment of moderate to severe RA.

All biologic DMARDs pose a risk for serious infections and perhaps cancer.

Abatacept is the only drug in its class.

Rheumatoid arthritis is not listed as an indication for tofacitinib (Xeljanz).

Sulfasalazine (Azulfidine) is a first-line drug for rheumatoid arthritis.

Leflunomide (Arava) is not indicated for systemic lupus erythematosus (SLE) or malaria.

Cyclosporine (Gengraf) does not require G6PD testing.

Tofacitinib (Xeljanz) carries a black box warning for serious or fatal infection risk, heart-related events, cancer, and blood clots.

Biologic DMARDs tend to have a delayed onset of 3-6 months for full therapeutic effect.

Methotrexate (Rheumatrex, Trexall) is indicated for the treatment of rheumatoid arthritis, psoriasis, juvenile idiopathic arthritis (JIA), and oncology.

Rituximab + methotrexate is indicated for subcutaneous therapy of adults with moderate to severe rheumatoid arthritis who have not responded to one or more TNF inhibitors.

Baricitinib (Olumiant) has a 16% risk of patients developing infection.

NSAIDs such as aspirin and celecoxib are not used in the management of gout.